Axtria Thought Leadership

Executive insights and perspectives on the Life Sciences industry
Aligning Sales to the Field Force with Accurate IC Sales Crediting

White Paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White Paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

Evolution of Pharmaceutical Call Planning

White Paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account-based call plans and how pharmaceutical companies must adapt to ensure their representatives are prepared and qual ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White Paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

White Paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

Traditional Call Planning

Blog

Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D

Axtria recently collaborated on a study to analyze the “Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome wit ...

Traditional Call Planning

Blog

Insightful HEOR Analysis For The Cardiovascular Community

Some of the most rewarding work we are involved in at Axtria right now is in the Health Economics and Outcomes Research (HEOR) space, where we are partnering with our clients to ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

Blog

Quantifying The Economic Burden Of IBS-D

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and e ...

Decision Science Asset Diversification Versus Concentration

White Paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...